Introduction
============

In 2012, approximately 951,000 individuals were diagnosed with gastric cancer (GC), which led to the death of 723,000 individuals worldwide [@B1]. Most patients are diagnosed with GC at a late stage when symptoms appear, and thus the prognosis is poor [@B2]: the median survival time for recurrent or metastatic GC remains less than 1 year. Recently, anti-angiogenesis agents have emerged as efficacious anti-tumor drugs against several tumor types, including colorectal cancer and GC. The RAINBOW trial, which compared the effects of paclitaxel with or without the anti-vascular endothelial factor receptor 2 (VEGFR2) monoclonal antibody ramucirumab in second-line chemotherapy for metastatic GC resulted in improved survival in the paclitaxel/ramucirumab arm [@B3]. Accordingly, the paclitaxel/ramucirumab combination is the current standard chemotherapy regimen for GC in a second-line setting. Because the prognosis remains poor after recurrence following curative surgery, identification of prognostic biomarkers associated with pivotal signaling pathways is crucial for enhancing survival for GC patients {Kim, 2018 \#2680}. The most widely prescribed anti-angiogenesis inhibitor is bevacizumab, which is a monoclonal antibody against the human VEGF ligand approved for use in the treatment colorectal and ovarian cancers. VEGF/VEGFR signaling inhibitors block VEGF-driven angiogenesis and thus regress VEGF-dependent tumor vessels. Nevertheless, VEGF inhibitors alone do not destroy all of the blood vessels in tumors. Indeed, clinical studies have demonstrated the emergence of resistance to anti-VEGF monotherapy [@B4], [@B5].

A few studies have identified the Notch signaling pathway as a newly emerging therapeutic tumor angiogenesis target [@B6]-[@B8]. Five ligands in the Notch signaling pathway (Jagged 1 and 2 and delta-like ligands 1, 3, and 4) are involved in tumorigenesis, tumor progression, tumor angiogenesis, and chemo-resistance. Among these, delta-like ligand 4 (DLL4) has received the most attention, and DLL4 inhibitors have been developed that show potent anti-tumor effects in a broad spectrum of VEGF therapy-resistant xenograft models [@B9]-[@B12]. Nevertheless, the prevalence of DLL4 expression in tumor specimens and its clinical implication in GC has not been extensively studied. Since this information is essential for identifying the potential target population for anti-DLL4 inhibitor treatment, in the present study, we surveyed the expression level of DLL4 using immunohistochemical (IHC) analysis in samples obtained from a large and well-defined cohort from the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial [@B13], and evaluated the association of DLL4 expression with patient survival.

Materials and Methods
=====================

Patients
--------

We used the ARTIST trial results for our analysis. The complete details of the ARTIST trial are published elsewhere [@B13]. In brief, 458 patients with pathological stage Ib-IV (M0) GC, according to the American Joint Committee on Cancer 2002 staging system, were randomly assigned to receive the adjuvant XP (*n* = 228) or XPRT (*n* = 230) treatment. The treatment regimen administered in the XP arm included six cycles of 1,000 mg/m^2^ capecitabine administered twice daily on days 1-14 and 60 mg/m^2^ cisplatin on day 1. The treatment regimen administered in the XPRT arm included concomitant administration of a total radiotherapy dose of 45 Gy and 825 mg/m^2^ capecitabine twice daily after completion of two cycles of XP, followed by administration of two additional cycles of XP. Written informed consent was obtained from all participating patients before they were randomly assigned to groups. A total of 336 specimens were available for further analysis in the present study.

IHC analysis
------------

Representative tumor areas were selected for all available samples, and a tissue microarray was constructed after reviewing a hematoxylin and eosin-stained section from the donor block. Using this slide for guidance, two representative regions of the tumor were sampled from the donor block, and 2-mm-diameter cores were extracted and embedded in the array block. Tumor sections from the array blocks were freshly cut into 3-µm slices, and dried at 60°C for 30 min. For DLL4 IHC, the slides were deparaffinized, and endogenous peroxidase was blocked for 5 min. Antigen retrieval was performed in an autoimmunostainer at 97°C for 20 min with ER1 buffer (pH 6.0). The slides were incubated with mouse DLL4 monoclonal antibody (HPA023392, 1:150, Sigma-Aldrich) at room temperature for 15 min using a BOND-MAX autoimmunostainer (Leica Microsystems, Wetzlar, Germany) and BOND Polymer Refine Detection kit (DS9800; Vision BioSystems, Melbourne, Australia).

Two well-experienced pathologists examined the IHC slides without prior information about the clinicopathological features of the patients. Semiquantitative estimates were achieved using a composite score comprised of the sum of the staining intensity values and the relative abundance of positive cells. The intensities were graded as 0 (negative), 1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). The abundance of positive cells was graded from 0 to 4 (0\<5 % positive cells; 1, 5-24 %; 2, 25-49 %; 3, 50-74 %; 4, 75-100 %). Based on the distribution of results, low and high DLL4 expression was defined if \<50% or ≥50% of the cells were stained with DLL4 monoclonal antibody, respectively (Fig. [1](#F1){ref-type="fig"}).

Statistical analyses
--------------------

The correlations between DLL4 expression and clinical characteristics were analyzed using the χ^2^ test or t-test as appropriate. In univariate survival analysis, the probability of disease‐free survival (DFS) or overall survival (OS) was determined by the Kaplan-Meier method. Because the median survival was not reached in several subgroups, Kaplan-Meier estimates of the 5‐year DFS and 5‐year OS are presented. Different survival curves were compared using the log‐rank test. Multivariate survival analysis was performed using the Cox proportional hazards regression model, including all variables that were significantly associated with patient survival in the univariate analysis along with patient age as an additional parameter. In general, *p* values \<0.05 were considered statistically significant. For statistical evaluation, we used the SPSS software package (version 10.0; SPSS, Inc., Chicago, IL, USA).

Results
=======

Relation of DLL4 expression with patient characteristics
--------------------------------------------------------

Of the 458 patients enrolled in the ARTIST trial, 336 had stage II, III, or IV GC, and these samples were included for analysis in the present study. The demographic and baseline characteristics of these patients are summarized in Table [1](#T1){ref-type="table"}. The median post-operative follow-up period of this cohort was 54.97 \[95% confidence interval (CI) 52.40-57.55\] months, with an observed mortality rate of 26.6% (89/336) after radical gastrectomy. The majority of patients were over 50 years of age and were men.

High DLL4 expression was detected in 67 (19.9%) of the 336 GC patients. Figure [1](#F1){ref-type="fig"} provides representative IHC staining images of DLL4 in GC tissues. The χ^2^ analysis showed that patients with Lauren\'s intestinal-type GC had higher expression of DLL4 than those with diffuse-type GC (***p*** \< 0.001). In addition, a significant correlation was observed between DLL4 expression and HER2 status (***p*** = 0.018). However, there was no significant correlation between DLL4 expression and other clinicopathological characteristics such as age, sex, tumor localization, Borrmann\'s classification, tumor status (pT), lymph node metastasis (pN), perineural invasion, or lymphovascular invasion (all *p* \> 0.05).

Impact of DLL4 expression on patient survival
---------------------------------------------

Kaplan-Meier survival curves were plotted separately for all patients (n = 336; (Fig. [2](#F2){ref-type="fig"}A, B), for those with stages II and IIIa GC (n = 269; Fig. [2](#F2){ref-type="fig"}C, D), and for those with stages IIIb and IV GC (n = 67; Fig. [2](#F2){ref-type="fig"}E, F). Stage II-IV GC patients with high DLL4 expression had significantly poorer DFS compared with those with low DLL4 expression \[median DFS, not reached (NR) for both cohorts, hazard ratio (HR) 0.73 (95% CI, 0.38-1.40); *p* = 0.007\], and the 5-year DFS rate of GC patients with low DLL4 expression (75.9%) was significantly better than that of patients harboring tumors with high DLL4 expression (63.5%). In addition, statistically significant differences in OS were observed for stage II-IV GC patients according to DLL4 expression, with a poor outcome for patients with a greater proportion of DLL4-stained cells \[HR 0.56 (95% CI, 0.32-0.96), *p* = 0.002\]. Neither DFS nor OS differed significantly according to DLL4 expression for patients with stage II and IIIa GC \[DFS: HR = 0.73 (95% CI, 0.38-1.40), *p* = 0.176; median OS: HR = 0.60 (95% CI, 0.30-1.22), *p* = 0.052\]. However, among patients with stages IIIb and IV GC, significantly shorter DFS and OS was associated with high DLL4 expression \[DFS: 34.87 vs. 10.10, HR = 0.44 (95% CI, 0.19-0.96), *p* = 0.004; OS: 58.87 vs. 16.93, HR = 0.39 (95% CI, 0.16-0.99), *p* = 0.001\].

Univariate and multivariate Cox regression analyses
---------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, univariate Cox regression analysis suggested that DLL4 expression, histological differentiation, Borrmann\'s classification, Lauren\'s classification, depth of invasion (pT), pN, TNM stage, and surgical resection were significantly associated with both OS and DFS. Multivariate regression with these eight significant variables further supported that high DLL4 expression, histologically poor differentiation and signet ring cell type, and advanced TNM stage (IIIb and IV) were independent prognostic factors of poor DFS. In addition, high DLL4 expression, Lauren\'s diffuse type, and advanced TNM stage (IIIb and IV) were independent prognostic factors of OS (Table [2](#T2){ref-type="table"}).

Discussion
==========

The overall results of this study suggest that high DLL4 expression is associated with a poor DFS and OS of GC patients following surgery. These results further imply that DLL4 expression may be correlated with metastases or recurrence following curative surgery in GC. Indeed, previous studies have shown that overexpression of DLL4 increased the risk of a poor clinical prognosis in other tumor types [@B14]-[@B18]. Thus, DLL4 may be a novel biomarker for predicting the prognosis and recurrence of GC.

Targeting tumor cell-specific DLL4 is a feasible anti-angiogenic treatment strategy by disrupting DLL4 in the tumor vasculature, along with direct effects on the frequency of tumor-initiating cells and tumor growth, either alone or in combination with chemotherapy [@B10]. Increased Notch1 activity has been reported in intestinal tumors [@B19]; in addition, we observed a high proportion of GC samples with high DLL4 expression. Taken together, these data implicate a role of DLL4 and the Notch signaling pathway in angiogenesis [@B20], [@B21] and suggest possible new targets for anti-angiogenic tumor therapy. Although clinical benefits of anti-VEGF therapy have been observed in patients with various types of cancers in terms of progression-free survival, the effects are variable, and acquired or innate resistance frequently occurs [@B22]-[@B25]. As an alternative, preclinical studies have demonstrated that blockade of DLL4 can have potent growth inhibitory effects on tumors that are resistant to anti-VEGF therapies [@B20], [@B26], [@B27]. Furthermore, simultaneous targeting of DLL4 and VEGF has shown additive anti-tumor effects compared to the effects of single agents in many tumor models [@B27]. Nevertheless, additional studies are warranted to ascertain the clinical validity of the combined treatment option.

Recent reports have demonstrated that DLL4 expression is related to the TNM stage, node stage, and distant metastasis, suggesting an association with poor prognosis in GC patients [@B28], [@B29]. By contrast, we did not find a correlation between DLL4 expression and clinicopathological parameters, including age, sex, smoking history, histological subtype, or tumor stage. This discrepancy between different studies may be related to limitations and differences in study designs. First, clinicopathological heterogeneity, such as distinct histological types, pathological stages, and different sample sizes among studies, may have affected the outcome of the analysis. Second, the difference in antibodies and IHC techniques used between studies may partly account for the different results. Third, the threshold of defining IHC-positive DLL4 expression differed among studies. Such unstandardized interpretation of the staining intensity and distribution, together with the use of various cut-off percentages to define DLL4 expression, ranging from ≥1% to ≥50%, likely contributed to this apparent contradiction in correlations.

Although we found that high DLL4 expression was an independent prognostic factor of OS and DFS in GC patients at an advanced TNM stage (IIIb and IV), it is important to note that the small number of patients at stage III/IV in this cohort makes it difficult to provide a strong conclusion based on this result, owing to the low power of the analysis. Thus, large-scale studies are needed to confirm the role of DLL4 expression as a predictive biomarker for GC, especially for patients with advanced disease. Likewise, further analysis of the co-expression and clinical effects of various angiogenic factors such as CD45 and PECAM-1 would be valuable, as these factors may further promote tumor proliferation and angiogenesis within tumor vessels.

Our findings suggest that anti-DLL4 antibodies may be a novel therapy that could even be used even as an initial treatment for cancers of the gastrointestinal tract. ABL001 is a recently developed bispecific antibody targeting both VEGF and DLL4, representing a potent anti-cancer therapeutic antibody. This antibody links each C-terminal of an anti-VEGF antibody (bevacizumab-similar) with a DLL4-binding single-chain variable fragment (scFv) [@B12]. ABL001 was shown to more effectively inhibit human A549 lung cancer and SCH GC cells in xenograft models than a VEGF-targeting antibody [@B12]. Based on our previous observations on the preclinical anti-tumor efficacy of the DLL4 inhibitor and the present findings of the impact of DLL4 expression on the survival of GC patients, we are currently conducting a phase I trial with ABL001 (clinicaltrials.gov; NCT03292783).

In summary, high DLL4 expression was observed in 19.9% of GC patients and was significantly associated with poor survival following curative surgery. Given the substantial prevalence of the protein in the GC cohort with a poor prognosis, DLL4 may be a potential novel prognostic indicator of GC and offers a new strategy for the treatment of GC.
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###### 

Patients and disease characteristics in the gastric cancer and according to DLL4 status.

  Characteristic                N=336 (%)    DLL 4 (low) n=269 (80.1%)   DLL 4 (high) n=67 (19.9%)   *p* value
  ----------------------------- ------------ --------------------------- --------------------------- -----------
  **Age**                                                                                            
  Median (range), years         57 (28-77)   56 (28-77)                  59 (33-77)                  0.104
  \< 60                         195 (58.0)   162 (60.2)                  33 (49.3)                   
  \>60                          141 (42.0)   107 (39.8)                  34 (50.7)                   
  **Sex**                                                                                            
  Male                          217 (64.6)   172 (63.9)                  45 (67.2)                   0.622
  Female                        119 (35.4)   97 (36.1)                   22 (32.8)                   
  **Tumor Localization**                                                                             0.296
  Cardias                       17 (5.1)     12 (4.5)                    5 (7.5)                     
  Body                          159 (47.3)   133 (49.4)                  26 (38.7)                   
  Antrum                        125 (37.2)   95 (35.3)                   30 (44.8)                   
  Whole/multiple                35 (10.4)    29 (10.8)                   6 (9.0)                     
  **Histology**                                                                                      0.042
  ADC,WD                        5 (1.5)      2 (0.7)                     3 (4.5)                     
  ADC,MD                        109 (32.4)   83 (30.9)                   26 (38.8)                   
  ADC,PD                        147 (43.8)   119 (44.2)                  28 (41.8)                   
  Signet ring cell              75 (22.3)    65 (24.2)                   10 (14.9)                   
  **Borrman classification**                                                                         
  1                             7 (2.1)      4 (1.5)                     3 (4.5)                     0.308
  2                             98 (29.2)    77 (28.6)                   21 (31.3)                   
  3                             193 (57.4)   156 (58.0)                  37 (55.2)                   
  4                             38 (11.3)    32 (11.9)                   6 (9.0)                     
  **Lauren type**                                                                                    
  Intestinal                    132 (39.2)   92 (34.2)                   40 (59.7)                   \< 0.001
  Diffuse                       189 (56.3)   164 (61.0)                  25 (37.3)                   
  Mixed                         15 (4.5)     13 (4.8)                    2 (3.0)                     
  **pT stage**                                                                                       
  1                             8 (2.4)      7 (2.6)                     1 (1.5)                     0.511
  2a                            64 (19.0)    54 (20.1)                   10 (14.9)                   
  2b                            158 (47.0)   120 (44.6)                  38 (56.7)                   
  3                             95(28.3)     79 (29.4)                   16 (23.9)                   
  4                             11 (3.3)     9 (3.3)                     2 (3.0)                     
  **pN stage**                                                                                       
  0                             13 (3.9)     11 (4.1)                    2 (3.0)                     0.130
  1                             202 (60.1)   165 (61.3)                  37 (55.2)                   
  2                             87 (25.9)    71 (26.4)                   16 (23.9)                   
  3                             34 (10.1)    22 (8.2)                    12 (17.9)                   
  **Stage**                                                                                          0.037
  II and IIIa                   271 (80.7)   223 (82.9)                  48 (71.6)                   
  IIIb and IV                   65 (19.3)    46 (17.1)                   19 (28.4)                   
  **Cer-b status**                                                                                   0.018
  negative                      281 (83.6)   226(84.0)                   55(82.1)                    
  positive                      18 (5.4)     9 (3.3)                     9 (13.4)                    
  unknown                       37 (11.0)    34 (12.6)                   3 (4.5)                     
  **Surgical resection**                                                                             0.929
  Subtotal                      199 (59.2)   159 (59.1)                  40 (59.7)                   
  Total                         137 (40.8)   110 (40.9)                  27 (40.3)                   
  **Perineural invasion**                                                                            
  No                            177 (52.5)   143(50.3)                   34 (50.7)                   0.743
  Yes                           159 (47.5)   126 (47)                    33 (49.3)                   
  **Lymphovascular invasion**                                                                        
  No                            106 (31.5)   86 (32.0)                   20 (29.9)                   0.738
  Yes                           230 (68.5)   183 (68.0)                  47 (70.1)                   

###### 

Prognostic factors associated with DFS and OS as determined by univariate and multivariate analysis

  DFS                              OS                                                                             
  -------------------------------- ----------------- --------- -------------------------------- ----------------- ---------
  ***Univariate analysis***                                    ***Univariate analysis***                          
  DLL 4 negative vs. positive      1.93(1.27-2.95)   0.002     DLL 4 negative vs. positive      1.95(1.24-3.08)   0.004
  \*Histological differentiation   1.72(1.10-2.67)   0.016     \*Histological differentiation   1.83(1.12-2.99)   0.015
  Borrman (1,2 vs 3,4)             1.85(1.33-2.56)   \<0.001   Borrman (1,2 vs 3,4)             2.16(1.52-3.08)   \<0.001
  Lauren intestinal vs. diffuse    1.53(1.10-2.14)   0.012     Lauren intestinal vs. diffuse    1.70(1.08-2.68)   0.019
  pT 1,2 vs. pT 3,4                2.26(1.54-3.30)   \<0.001   pT 1,2 vs. pT 3,4                2.46(1.62-3.73)   \<0.001
  pN 0,1 vs. pN 2,3                2.73(1.87-4.00)   \<0.001   pN 0,1 vs. pN 2,3                2.57(1.69-3.90)   \<0.001
  Stage(II/IIIa versus IIIb/IV)    3.82(2.58-5.65)   \<0.001   Stage(II/IIIa versus IIIb/IV)    3.55(2.31-4.56)   \<0.001
  Surgical resection TG vs STG     1.70(1.16-2.47)   0.007     Surgical resection TG vs STG     1.84(1.22-2.80)   0.004
  ***Multivariate analysis***                                  ***Multivariate analysis***                        
  DLL 4 negative vs. positive      1.80(1.14-2.86)   0.012     DLL 4 negative vs. positive      2.07(1.23-3.46)   0.006
  \*Histological differentiation   1.78(1.10-2.89)   0.021     Lauren intestinal vs. diffuse    2.19(1.30-3.69)   0.003
  Stage(II/IIIa versus IIIb/IV)    3.95(2.56-6.11)   \<0.001   Stage(II/IIIa versus IIIb/IV)    3.93(2.45-6.32)   \<0.001
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